Jan, 25th 2021 – Kenya is one of the 92 countries set to receive the Pfizer vaccine. This is following the announcement of an agreement between American multinational pharmaceutical corporation Pfizer and BioNTech SE with the Covax Facility.
Kenya had applied for 24 million vaccines and could either get the Oxford/AstraZeneca vaccine or the Pfizer BioNTech depending on the distribution by the Covax Facility.
Covax, a global initiative coordinated by the Global Alliance for Vaccines and Immunisation, the Coalition for Epidemic Preparedness Innovations, and the World Health Organization, is meant to ensure equitable access to Covid-19 vaccines for all countries, regardless of income levels.
This new development comes after Pfizer announced an advance purchase agreement with Covax Facility for up to 40 million doses of the Pfizer-BioNTech Covid-19 Vaccine. The company said the doses will be delivered throughout 2021.
Pfizer Chairman and CEO Albert Bourla said, “At Pfizer, we believe that every person deserves to be seen, heard, and cared for. That’s why from the very beginning of our vaccine development program, Pfizer and BioNTech have been firmly committed to working toward equitable and affordable access of Covid-19 vaccines for people around the world.”
The government, here in Kenya has announced that it will vaccinate as per the African Union (AU) guidelines, which state that frontline workers will have priority to receive the limited doses of vaccine ordered.
According to the WHO Regional Director for Africa, Dr. Matshidiso Moeti, Africa is in danger of being left behind as countries in other regions strike bilateral deals, driving up prices.